RECRUITING

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Description

The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.

Conditions

Epidermolysis BullosaEpidermolysis Bullosa AcquisitaDystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis Bullosa
Talk to us

Related Conditions:

Epidermolysis BullosaEpidermolysis Bullosa AcquisitaDystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis Bullosa

Study Overview

On this page

Study Details

Study overview

The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Condition
Epidermolysis Bullosa
Intervention / Treatment

-

Contacts and Locations

Redwood City

Stanford University, Redwood City, California, United States, 94163

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Diagnosis of generalized Recessive dystrophic epidermolysis bullosa (RDEB) demonstrated by COL7A1 mutations.
  • 2. Diagnosis of EBA demonstrated by the presence of levels of serum C7 antibodies above the normal ELISA range
  • 3. Baseline skin blistering greater than 5% total body surface area
  • 4. 1 wound at least 20 cm\^2 able to be entirely treated with Vyjuvek weekly
  • 5. 1 wound at least 20 cm\^2 that has never been treated with Vyjuvek
  • 6. Ongoing VYJUVEK treatment.
  • 1. History of thrombotic event(s)
  • 2. History of cardiac failure
  • 3. History of renal failure
  • 4. IgA deficiency

Ages Eligible for Study

6 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

M. Peter Marinkovich,

Matt P Marinkovich, MD, PRINCIPAL_INVESTIGATOR, Associate Professor of Dermatology

Study Record Dates

2026-03-06